Core Laboratories (CLB) to Release Earnings on Wednesday
Core Laboratories (NYSE:CLB) is set to release its earnings data after the market closes on Wednesday, October 23rd. Analysts expect Core Laboratories to post earnings of $0.49 per share for the quarter. Core Laboratories has set its Q3 2019 guidance at $0.48-0.52 EPS and its Q3 guidance at $0.48-0.52 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.
Core Laboratories (NYSE:CLB) last posted its quarterly earnings results on Wednesday, July 24th. The oil and gas company reported $0.46 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.46. Core Laboratories had a net margin of 14.30% and a return on equity of 51.19%. The firm had revenue of $169.04 million for the quarter, compared to analysts’ expectations of $173.46 million. During the same quarter in the prior year, the company posted $0.59 earnings per share. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, analysts expect Core Laboratories to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
NYSE:CLB opened at $42.06 on Tuesday. The company’s 50 day moving average price is $44.70 and its 200-day moving average price is $51.32. Core Laboratories has a 52 week low of $36.61 and a 52 week high of $102.12. The company has a quick ratio of 1.41, a current ratio of 1.80 and a debt-to-equity ratio of 1.83. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 4.59 and a beta of 1.97.
In related news, Director Gregory Barry Barnett bought 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were bought at an average price of $40.00 per share, for a total transaction of $40,000.00. Following the completion of the acquisition, the director now owns 11,000 shares of the company’s stock, valued at approximately $440,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.00% of the company’s stock.
CLB has been the topic of a number of recent analyst reports. Piper Jaffray Companies set a $52.00 target price on shares of Core Laboratories and gave the stock a “hold” rating in a report on Wednesday, June 26th. Morgan Stanley dropped their target price on shares of Core Laboratories from $65.00 to $55.00 and set an “equal weight” rating on the stock in a report on Monday, October 7th. Bank of America upgraded shares of Core Laboratories from a “neutral” rating to a “buy” rating and set a $63.00 target price on the stock in a report on Wednesday, July 10th. ABN Amro cut shares of Core Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, October 17th. Finally, ValuEngine upgraded shares of Core Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Ten investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Core Laboratories has an average rating of “Hold” and a consensus price target of $72.58.
About Core Laboratories
Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Recommended Story: Does the Dogs of the Dow strategy work?
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.